2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
George R. Blumenschein, MD, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combinations with immunotherapy for patients with non-small cell lung cancer (NSCLC).
George R. Blumenschein, MD, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combinations with immunotherapy for patients with non-small cell lung cancer (NSCLC).
Immunotherapy is being combined in numerous different ways, either with other immunotherapy regimens or with chemotherapy, explains Blumenschein.
Combinations are being investigated in clinical trials for patients who are not candidates for single-agent immunotherapy. There will be a shift to use more immunotherapy in the frontline setting, states Blumenschein.